

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Ephrin B2 (EFNB2)	<p><i>In vitro</i> and mouse studies suggest that inhibiting EFB2 could be antiangiogenic and could help treat cancer. As compared with wild-type controls, mice with a deficiency in Efnb2 signaling or endothelial cell-specific <i>Efnb2</i> knockout had reduced endothelial cells available for angiogenesis and cell sprouting. <i>In vitro</i>, EFNB2 deficiency prevented signaling by the VEGF receptor and reduced angiogenesis compared with normal EFNB2 expression. Next steps include screening small molecule inhibitors or activators of EFNB2 for activity <i>in vitro</i> and in angiogenic assays.</p> <p><b>SciBX 3(20); doi:10.1038/scibx.2010.614</b>  <b>Published online May 20, 2010</b></p>	<p>Findings in first study unpatented; unavailable for licensing</p> <p>Patent and licensing status for findings in second study unavailable</p>	<p>Sawamiphak, S. <i>et al. Nature</i>; published online May 5, 2010; doi:10.1038/nature08995  <b>Contact:</b> Amparo Acker-Palmer, Goethe University Frankfurt, Frankfurt, Germany            e-mail: <a href="mailto:Acker-Palmer@bio.uni-frankfurt.de">Acker-Palmer@bio.uni-frankfurt.de</a></p> <p>Wang, Y. <i>et al. Nature</i>; published online May 5, 2010; doi:10.1038/nature09002  <b>Contact:</b> Ralf Adams, Max Planck Institute for Molecular Biomedicine, Muenster, Germany            e-mail: <a href="mailto:ralf.adams@mpi-muenster.mpg.de">ralf.adams@mpi-muenster.mpg.de</a></p>